Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Center for Primary Health Care Research, Lund University/Region Skåne, Sweden.
Curr Med Chem. 2021;28(11):2175-2194. doi: 10.2174/0929867327999200820124111.
Drug repurposing, the application of known drugs and compounds with a primary non-oncology purpose, might be an attractive strategy to offer more effective treatment options to cancer patients at a low cost and reduced time.
This review described a total of 10 kinds of non-oncological drugs from more than 100 mechanical studies as well as evidence from population-based studies. The future direction of repurposed drug screening is discussed by using patient-derived tumor organoids.
Many old drugs showed previously unknown effects or off-target effects and can be intelligently applied for cancer chemoprevention and therapy. The identification of repurposed drugs needs to combine evidence from mechanical studies and population-based studies. Due to the heterogeneity of cancer, patient-derived tumor organoids can be used to screen the non-oncological drugs in vitro.
These identified old drugs could be repurposed in oncology and might be added as adjuvants and finally benefit patients with cancers.
药物重定位，即将具有主要非肿瘤学用途的已知药物和化合物应用于肿瘤治疗，可能是一种极具吸引力的策略，可以以较低的成本和较短的时间为癌症患者提供更有效的治疗选择。
本综述共描述了来自 100 多项机械研究以及基于人群的研究证据的 10 种非肿瘤药物。通过使用患者来源的肿瘤类器官探讨了重新定位药物筛选的未来方向。
许多老药物显示出以前未知的作用或脱靶作用，可被智能地应用于癌症化学预防和治疗。重新定位药物的识别需要结合机械研究和基于人群的研究证据。由于癌症的异质性，患者来源的肿瘤类器官可用于体外筛选非肿瘤药物。
这些已确定的老药物可在肿瘤学中重新定位，并可作为辅助药物最终使癌症患者受益。
